Diabetic macular edema: A review of past, present, and future therapies

International Ophthalmology Clinics

Volumn 44, Issue 4, 2004, Pages 51-67

  Thompson, Matthew J ^a   Ip, Michael S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOCINOLONE ACETONIDE; INSULIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TRIAMCINOLONE ACETONIDE;

ABDOMINAL DISCOMFORT; CATARACT; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIODE LASER; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENDOPHTHALMITIS; FLUORESCENCE ANGIOGRAPHY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMPLANTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; METAPLASIA; PATHOGENESIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; SCOTOMA; SIDE EFFECT; SMOKING CESSATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL DISORDER; VITRECTOMY;

DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA, CYSTOID;

EID: 6344272096     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404440-00006     Document Type: Review

References (51)

1. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136:122-135.
2. From the Centers for Disease Control and Prevention. Blindness caused by diabetes - Massachusetts, 1987-1994. JAMA. 1996;276:1865-1866.
3. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
5. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102:647-661.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405-412.
7. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
8. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061-1070.
9. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J. 2000;321:412-419.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713 [erratum in: Br Med J. 1999;318:29].
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713 [erratum in: Br Med J. 1999;318:29].
12. Klein R, Klein BE, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med. 1989;149:2427-2432.
13. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34-40.
14. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112:385-391.
15. McDonald HR, Schatz H. Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 1985;92:388-393.
16. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
17. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274:23463-23467.
18. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
19. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
20. Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473-478.
21. Tachi N. Surgical management of macular edema. Semin Ophthalmol. 1998;13:20-30.
22. Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol. 1998;9:71-75.
23. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178-186.
24. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369-377.
25. Ikeda T, Sato K, Katano T, et al. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999;127:478-479.
26. Harbour JW, Smiddy WE, Flynn HW Jr, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405-413.
27. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987;94:761-774.
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
29. Schatz H, Madeira D, McDonald HR, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551.
30. Mainster MA, White TJ, Tips JH, et al. Retinal-temperature increases produced by intense light sources. J Opt Soc Am. 1970;60:264-270.
31. Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14:19-26.
32. Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye. 1999;13:145-150.
33. Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology. 1997;104:2030-2038.
34. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335-1339.
35. Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753-759.
36. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122:258-260.
37. Aiello LP, Pierce EA, Foley ED, et al. Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci USA. 1995;92:10457-10461.
38. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
39. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of VEGF prevent ocular neovascularization in a non-human primate. Arch Ophthalmol. 1996;114:66-71.
40. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
41. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
42. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol. 1997;16:398-406.
43. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
44. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61.
45. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-224.
46. Butcher JM, Austin M, McGalliard J, et al. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. Br Med J. 1994;309:43.
47. Gardner TW, Antonetti DA, Barber AJ, et al. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601-608.
48. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791-804.
49. Naveh-Floman N, Weissman C, Belkin M. Arachidonic acid metabolism by retinas of rats with streptozotocin-induced diabetes. Curr Eye Res. 1984;3:1135-1139.
50. Ershov AV, Bazan NG. Induction of cyclooxygenase-2 gene expression in retinal pigment epithelium cells by photoreceptor rod outer segment phagocytosis and growth factors. J Neurosci Res. 1999;58:254-261.
51. Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:2338-2346.